DataString Consulting Company Logo
DataString Consulting Company Logo
Sparsentan Tablets Market
Home»Top Market Reports»Sparsentan Tablets Market

Sparsentan Tablets Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802084, Published - March 2025

Segmented in Therapeutic Use (Chronic Kidney Disease, Focal Segmental Glomerulosclerosis), Patient Age Group (Pediatrics, Adults, Geriatrics), Prescription Type, Dosage Form, Treatment Duration and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Sparsentan Tablets Market Outlook

The market, for Sparsentan tablets was estimated at $2.4 billion in 2024; and it is anticipated to increase to $4.3 billion by 2030 with projections indicating a growth to around $7.1 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 10.5% over the forecast period. The strong upward trend in the Sparsentan tablets market reflects its performance and continued importance in the pharmaceutical industry landscape. This development is mainly driven by factors such as the growing incidence of focal segmental glomerulosclerosis (FSGS) rising need for efficient medications progress, in drug formulation methods and increasing healthcare investments globally. Additionally the market momentum is bolstered by the products features, potent pharmacological effects and supportive regulations and guidelines established by regulatory bodies for orphan drugs.


Sparsentan tablets are medications aimed at treating conditions such as focal segmental glomerulosclerosis and IgA nephropathy that present complex challenges for doctors and patients alike. The medication works by targeting proteinuria. A factor in the progression of these illnesses through its unique dual mechanism of action. Also it leverages drug formulation technologies and recent trends show an increasing demand for the drug due to rising awareness, about these diseases and the perceived shortcomings of current treatment options.


Market Size Forecast & Key Insights

2019
$2.4B2024
2029
$6.4B2034

Absolute Growth Opportunity = $4.1B

The Sparsentan Tablets market is projected to grow from $2.4 billion in 2024 to $6.4 billion in 2034. This represents a CAGR of 10.5%, reflecting rising demand across Treatment of Focal Segmental Glomerulosclerosis (FSGS), Management of Hypertension and Treatment of IgA Nephropathy.

The Sparsentan Tablets market is set to add $4.1 billion between 2024 and 2034, with manufacturer targeting Adults & Geriatrics Patient Age Group projected to gain a larger market share.

With Rising incidence of kidney disorders, and Technological advancements in drug delivery systems, Sparsentan Tablets market to expand 171% between 2024 and 2034.

Opportunities in the Sparsentan Tablets Market

Strategic Collaborations

By working with both local and global pharmaceutical firms strategically the market visibility of Sparsentan tablets could be enhanced significantly. Collaborations allow for the exchange of expertise pooling of resources and the efficient and affordable advancement of Sparsentan tablets into markets. This approach also aids in meeting the increasing need, for Sparsentan tablets and enhancing their availability worldwide.

Technological Advancements in Production and Expansion into Untapped Geographic Segments

The field of pharmaceuticals is always. Improving as new technologies are used to make drugs such as Sparsentan tablets more efficiently and effectively produced by manufacturers. These advancements offer chances for companies to improve their operations by using innovative methods that help them produce more quickly and at lower costs while maintaining the high quality of Sparsentan tablets. By embracing these approaches and technologies in production processes, for Sparsentan tablets could lead to capturing a larger market share and driving up sales figures.

The latest trends in the market show that there is an opportunity for Sparsentan tablets to expand into new geographic areas that havent been explored yet. This is especially true, for developing countries where there are growing healthcare budgets and more people needing treatment choices. If companies start selling their products in these places it can lead to reaching a group of potential customers and boosting sales.

Growth Opportunities in North America and Europe

Europe Outlook

Europe plays a role in the market for Sparsentan tablets due to its organized pharmaceutical sector and increasing emphasis on patient centered care practices. The strong healthcare infrastructure and substantial healthcare spending in European nations create a favorable market landscape for Sparsentan tablets. The high incidence of kidney diseases and the need for effective treatment options highlight the broad potential, for the widespread use of Sparsentan tablets. Moreover the aging population in Europe sets the stage for embracing cutting edge treatments and further establishes the significance of Sparsentan tablets in healthcare practices More so partnerships, between pharmaceutical firms and research organizations lead to robust competition underscoring the ever evolving landscape of the industry.

North America Outlook

Being a hub of groundbreaking advancements and breakthroughs in healthcare innovation makes North America an important market for Sparsentan tablets consumption. The established healthcare system and cutting edge medical practices in this region play a crucial role in driving the market for Sparsentan tablets forward. Ongoing clinical trials add a competitive advantage to key industry players. The prevalence of kidney diseases such as Focal Segmental Glomerulosclerosis and Immunoglobin A Nephropathy serves as a catalyst for the market growth by highlighting the need for effective treatments, like Sparsentan. Moreover​ ​The rise in the availability of health insurance plans, in this region enhances the accessibility of these medications​​​​​. This helps to promote greater utilization of Sparsentan tablets.

North America Outlook

Being a hub of groundbreaking advancements and breakthroughs in healthcare innovation makes North America an important market for Sparsentan tablets consumption. The established healthcare system and cutting edge medical practices in this region play a crucial role in driving the market for Sparsentan tablets forward. Ongoing clinical trials add a competitive advantage to key industry players. The prevalence of kidney diseases such as Focal Segmental Glomerulosclerosis and Immunoglobin A Nephropathy serves as a catalyst for the market growth by highlighting the need for effective treatments, like Sparsentan. Moreover​ ​The rise in the availability of health insurance plans, in this region enhances the accessibility of these medications​​​​​. This helps to promote greater utilization of Sparsentan tablets.

Europe Outlook

Europe plays a role in the market for Sparsentan tablets due to its organized pharmaceutical sector and increasing emphasis on patient centered care practices. The strong healthcare infrastructure and substantial healthcare spending in European nations create a favorable market landscape for Sparsentan tablets. The high incidence of kidney diseases and the need for effective treatment options highlight the broad potential, for the widespread use of Sparsentan tablets. Moreover the aging population in Europe sets the stage for embracing cutting edge treatments and further establishes the significance of Sparsentan tablets in healthcare practices More so partnerships, between pharmaceutical firms and research organizations lead to robust competition underscoring the ever evolving landscape of the industry.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Canada, Britain, Australia, Germany are expected to grow at 7.7% to 11.0% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 10.1% to 13.1% CAGR

Market Analysis Chart

Its important to grasp the factors influencing the market for Sparsentan tablets as they offer valuable insights into how the drug is performing in the market dynamics scenario currently. One significant factor driving the demand for Sparsentan tablets is the increasing occurrence of kidney diseases such, as Focal Segmental Glomerulosclerosis a condition where Sparsentan has shown to be effective.

Recent Developments and Technological Advancement

December 2024

AstraZeneca revealed the FDAs light for their Sparsentan tablets known for their effectiveness, in treating primary FSGS .

October 2024

Sanofi announced results from phase 3 trials showing that Sparsentan tablets effectively treat IgNephropathy.

August 2024

Merck announced a collaboration with research institutions globally to carry out in depth clinical trials, on their Sparsentan tablets aiming to expand their potential benefits.

In the few years the field of pharmaceuticals has witnessed numerous important advancements especially in the treatment of nephrotic syndrome, with Sparsentan tablets gaining popularity as a unique dual action antagonist known for its innovative approach and promising advantages.

Impact of Industry Transitions on the Sparsentan Tablets Market

As a core segment of the Pharmaceutical industry, the Sparsentan Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Shift towards Personalized Medicine and Ramp up in Digital Health Technologies have redefined priorities across the Pharmaceutical sector, influencing how the Sparsentan Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Shift towards Personalized Medicine:

The pharmaceutical industry is experiencing changes in its operations due to the rise of precision medicine. The impact of this change is particularly seen in medications such as Sparsentan tablets which are designed for treating kidney ailments. The move towards customized medicine has spurred the creation of personalized drugs to cater to treatment needs. This shift has also heightened competition, among companies as they strive to innovate and adapt their products to match the advancements in this field.

2

Ramp up in Digital Health Technologies:

The digital transformation trends in healthcare have impacted the Sparsentan tablet and its related pharmaceutical market significantly. With the rise of health tools came advancements in monitoring drug effectiveness and side effects as well as ensuring patient compliance with medication schedules. This modern approach has played a role, in transforming how Sparsentan tablets are prescribed and managed leading to improved patient care and treatment results.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Sparsentan Tablets market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Incidence of Kidney Disorders

The rise in kidney problems like Focal Segmental Glomerulosclerosis has also led to a growing need for effective treatments such as Sparsentan tablets on the market today that target specific pathways in kidney disorders with promising potential for effective patient care management. This increasing trend of kidney diseases highlights the demand for treatment choices like Sparsentan tablets, in the healthcare sector.
Advancements in drug delivery technology have also expanded the effectiveness of Sparsentan tablets by introducing modified release versions that improve compliance through less frequent dosages and better treatment results leading to increased market demand, for Sparsentan tablets.

Restraint: Regulatory Hurdles

One of the challenges facing Sparsentan tablets in the market is dealing with the strict regulations in the pharmaceutical industry. Since Sparsentan is relatively new to the market scenario compared to established products and brands out there the process of gaining acceptance from important players can be quite tough. Meeting the standards set by regulatory bodies like FDA and EMA requires going through extensive clinical trials and ensuring safety measures are in place. A process that often hinders the speed at which Sparsentan can establish itself in the market. Following manufacturing protocols along with quality control measures and distribution guidelines adds another layer of difficulty in getting approval and recognition for Sparsantane tablets, in the market. This has an effect, on its market appeal and the ever evolving path of growth.

Challenge: Limited Awareness and Market Penetration

Sparsentans special significance in the treatment of glomerular conditions, like focal segmental glomerulosclerosis and IgAN isnt fully acknowledged at this time.

Supply Chain Landscape

Raw Material Procurement

Pfizer

Merck & Co

API Production

Vertex Pharmaceuticals

GlaxoSmithKline

Tablet Formulation
AstraZeneca / Novartis
Distribution & Sale
Walgreens Boots Alliance / CVS Health
Raw Material Procurement

Pfizer

Merck & Co

API Production

Vertex Pharmaceuticals

GlaxoSmithKline

Tablet Formulation

AstraZeneca

Novartis

Distribution & Sale

Walgreens Boots Alliance

CVS Health

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Pharmaceuticals
Travere Therapeutics
The development of molecule DR as a potential first-line treatment for FSGS, adopting a patient-centric approach, partnering with leading healthcare providers to ensure the reach and efficacy of Sparsentan tablets
Management of IgA Nephropathy
Pharmaceuticals
Travere Therapeutics
Capitalizing on the sparsentan's dual mechanism of action to control proteinuria and slow the progression of IgA Nephropathy, including innovative solutions into care plans, partnering with health facilities to increase accessibility
Hypertension Control
Pharmaceuticals
Travere Therapeutics
Leveraging Sparsentan's angiotensin receptor blocker properties to control hypertension, focusing on partnerships for better disease management and accessibility to Sparsentan tablets

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Sparsentan Tablets market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Sparsentan Tablets in Management of Hypertension, Treatment of IgA Nephropathy and Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Management of Hypertension

Moreover Sparsentan tablets are used to treat blood pressure due to their ability to block both angiotensin and endothelin receptors simultaneously. Companies such as Ligand Pharmaceuticals have solidified their position in the market by utilizing Sparsentans effectiveness, in managing hypertension and showcasing their expertise in cutting edge research and development.

Treatment of IgA Nephropathy

Sparsentan tablets are commonly used to treat IgAN a kidney disease characterized by high levels of protein in the urine . These tablets help decrease proteinuria and improve kidney health in individuals with IgAN symptoms like to preserve renal function effectively demonstrated by leading companies, like Retrophin who have shown significant success using Sparsentan for IgAN management.

Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Sparsentan tablets have been recognized for their effectiveness in treating Focal Segmental Glomerulosclerosis a condition that affects the kidneys and is considered rare in terms. The unique feature of Sparsentan tablets lies in their ability to address protein leakage in the urine through a mechanism of action that helps slow down the progression of this disease. Key players like Travere Therapeutics have established a presence, in the market by focusing on developing drugs for uncommon illnesses and capitalizing on the therapeutic potential of Sparsentan tablets specifically for managing FSGS.

Sparsentan Tablets vs. Substitutes:
Performance and Positioning Analysis

Sparsentan tablets differentiate due to their dual-action mechanism addressing proteinuria in kidney diseases, providing an edge over single-action alternatives. Its unique market positioning enables potential growth in hypertension treatment. These Alternatives specially Irbesartan Tablets has experienced a rapid growth as detailed in our latest report.

Sparsentan Tablets
  • Irbesartan Tablets /
  • Candesartan tablets /
  • Telmisartan tablets
    Effective treatment for focal segmental glomerulosclerosis and IgA nephropathy, Potential to lower proteinuria rates
    Effective treatment for chronic kidney conditions, often less expensive
    potential side effects, less studied long-term safety profile

Sparsentan Tablets vs. Substitutes:
Performance and Positioning Analysis

Sparsentan Tablets

  • Effective treatment for focal segmental glomerulosclerosis and IgA nephropathy, Potential to lower proteinuria rates

Irbesartan Tablets / Candesartan tablets / Telmisartan tablets

  • Effective treatment for chronic kidney conditions, often less expensive
  • potential side effects, less studied long-term safety profile

Sparsentan tablets differentiate due to their dual-action mechanism addressing proteinuria in kidney diseases, providing an edge over single-action alternatives. Its unique market positioning enables potential growth in hypertension treatment. These Alternatives specially Irbesartan Tablets has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Sparsentan Tablets market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Sparsentan Tablets across Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Retrophin Inc., Sanofi S.A., and Boehringer Ingelheim by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Production, and Tablet Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Sparsentan Tablets segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Pfizer, Merck & Co), API Production (Vertex Pharmaceuticals, GlaxoSmithKline), and Tablet Formulation. Our parallel substitute analysis examines Irbesartan Tablets, Candesartan tablets, and Telmisartan tablets, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Retrophin Inc., Sanofi S.A., and Boehringer Ingelheim, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Sparsentan Tablets market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Sparsentan Tablets Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 2.6 billion
Revenue Forecast in 2034USD 6.4 billion
Growth RateCAGR of 10.5% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 20242.4 billion
Growth OpportunityUSD 4.1 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 20242.4 billion USD
Market Size 20273.2 billion USD
Market Size 20293.9 billion USD
Market Size 20304.3 billion USD
Market Size 20346.4 billion USD
Market Size 20357.1 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredTherapeutic Use, Patient Age Group, Prescription Type, Dosage Form, Treatment Duration
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledRetrophin Inc., Sanofi S.A., Boehringer Ingelheim, Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Bayer AG, Merck & Co. Inc., AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson and Eli Lilly and Company.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Sparsentan Tablets Market Size, Opportunities & Strategic Insights, by Therapeutic Use

4.1Chronic Kidney Disease
4.2Focal Segmental Glomerulosclerosis
Chapter 5

Sparsentan Tablets Market Size, Opportunities & Strategic Insights, by Patient Age Group

5.1Pediatrics
5.2Adults
5.3Geriatrics
Chapter 6

Sparsentan Tablets Market Size, Opportunities & Strategic Insights, by Prescription Type

6.1Hospital Pharmacy
6.2Retail Pharmacy
6.3Online Pharmacy
Chapter 7

Sparsentan Tablets Market Size, Opportunities & Strategic Insights, by Dosage Form

7.1Low Dose
7.2Medium Dose
7.3High Dose
Chapter 8

Sparsentan Tablets Market Size, Opportunities & Strategic Insights, by Treatment Duration

8.1Short-term
8.2Long-term
8.3Extended Duration
Chapter 9

Sparsentan Tablets Market, by Region

9.1North America Sparsentan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Sparsentan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Sparsentan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Sparsentan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Sparsentan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Sparsentan Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Retrophin Inc.
10.2.2Sanofi S.A.
10.2.3Boehringer Ingelheim
10.2.4Novartis AG
10.2.5Pfizer Inc.
10.2.6Bristol-Myers Squibb Company
10.2.7Bayer AG
10.2.8Merck & Co. Inc.
10.2.9AstraZeneca
10.2.10GlaxoSmithKline plc.
10.2.11Johnson & Johnson
10.2.12Eli Lilly and Company.